Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

3.5%

11 terminated/withdrawn out of 318 trials

Success Rate

96.2%

+9.6% vs industry average

Late-Stage Pipeline

46%

146 trials in Phase 3/4

Results Transparency

78%

215 of 276 completed trials have results

Key Signals

9 recruiting215 with results7 terminated4 withdrawn

Enrollment Performance

Analytics

N/A

97(32.6%)

Phase 4

77(25.8%)

Phase 3

69(23.2%)

Phase 2

41(13.8%)

Phase 1

13(4.4%)

Early Phase 1

1(0.3%)

298Total

N/A(97)

Phase 4(77)

Phase 3(69)

Phase 2(41)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (318)

Showing 20 of 318 trials

NCT06665477Not ApplicableCompleted

Evaluate the Effectiveness and Safety of Restylane Volyme in the Treatment of Temple Hollowing

Role: lead

NCT07074977Phase 2Active Not Recruiting

Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

Role: lead

NCT07720726Phase 4Not Yet Recruiting

Impact of Dysport on PMFF Donor Scar

Role: collaborator

NCT04162496Not ApplicableCompleted

Restylane Refyne for Correction of Horizontal Neck Rhytides

Role: collaborator

NCT04717934Not ApplicableCompleted

Main Study: A Study to Evaluate the Effectiveness and Safety of GAL1906 for Correction of Wrinkles in the décolletage Area Sub-study: A Follow-up Study to Evaluate the Analysis of Mammograms Following Treatment for Correction of Wrinkles in Décolletage Area in the Investigational Study 43USRV1906

Role: lead

NCT07566286Not ApplicableNot Yet Recruiting

Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region

Role: lead

NCT04921345Phase 2Completed

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

Role: lead

NCT07660835Phase 2Not Yet Recruiting

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis

Role: lead

NCT07047638Not ApplicableActive Not Recruiting

A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine

Role: lead

NCT05463978Completed

Sculptra Chart Review

Role: lead

NCT06357221Phase 4Completed

A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients

Role: lead

NCT06988618Recruiting

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

Role: lead

NCT04365387Phase 2Completed

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

Role: lead

NCT05148000Phase 3Completed

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

Role: lead

NCT05777759Not ApplicableCompleted

Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile

Role: lead

NCT05691972Not ApplicableCompleted

Effectiveness and Safety of Restylane Contour in the Treatment of Temple Hollowing

Role: lead

NCT05110287Completed

To Evaluate Effectiveness and Safety of GP0109 for Jawline Definition

Role: lead

NCT06015217Phase 4Completed

A Clinical Study to Assess the Efficacy and Safety of a Healing Ointment on Diaper Rash

Role: lead

NCT05622851Not ApplicableCompleted

Comparative Ultrasound Analysis of Two Hyaluronic Acid Dermal Fillers

Role: lead

NCT03713203Not ApplicableRecruiting

PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Paget's Disease of the Vulva (EMPV).

Role: collaborator